Mark Schoenberg - Jan 31, 2023 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Medical Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Jan 31, 2023
Transactions value $
-$19,228
Form type
4
Date filed
2/2/2023, 12:02 PM
Previous filing
Jan 23, 2023
Next filing
Jun 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +500 +0.34% 147K Jan 31, 2023 Direct F1
transaction URGN Ordinary Shares Sale -$2.51K -248 -0.17% $10.12 147K Jan 31, 2023 Direct F7
transaction URGN Ordinary Shares Options Exercise +2K +1.36% 149K Jan 31, 2023 Direct F1
transaction URGN Ordinary Shares Sale -$10K -991 -0.67% $10.12 148K Jan 31, 2023 Direct F7
transaction URGN Ordinary Shares Options Exercise +1.33K +0.9% 149K Jan 31, 2023 Direct F1
transaction URGN Ordinary Shares Sale -$6.69K -661 -0.44% $10.12 149K Jan 31, 2023 Direct F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -500 -100% $0.00* 0 Jan 31, 2023 Ordinary Shares 500 Direct F1, F2
transaction URGN Restricted Stock Units Options Exercise $0 -2K -50% $0.00 2K Jan 31, 2023 Ordinary Shares 2K Direct F1, F3
transaction URGN Restricted Stock Units Options Exercise $0 -1.33K -33.32% $0.00 2.67K Jan 31, 2023 Ordinary Shares 1.33K Direct F1, F4
transaction URGN Restricted Stock Units Award $0 +10K $0.00 10K Jan 31, 2023 Ordinary Shares 10K Direct F1, F5
transaction URGN Employee Stock Option (right to buy) Award $0 +30K $0.00 30K Jan 31, 2023 Ordinary Shares 30K $10.39 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.
F3 The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022.
F4 The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023.
F5 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026.
F6 1/3 of the shares underlying the stock options will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026.
F7 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.